Nutzung von Daten aus der Pharmakovigilanz durch das Paul-Ehrlich-Institut zur Bewertung von COVID-19-Impfstoffen

This procedure is a written question aimed at clarifying how the Paul-Ehrlich-Institut uses pharmacovigilance data—the monitoring of drug side effects—to evaluate the safety and effectiveness of COVID-19 vaccines. This affects public health oversight and ensures transparency regarding how national health authorities monitor vaccine safety for the general population.